NORTH BRIDGE VENTURE PARTNERS V-B LP

CIK 00011383995 companiesWALTHAM, MA

SEC Profile

Transactions

Companies

Filings

CIK

0001138399

Recent Transactions

50 trades

Purchase
Lyra Therapeutics, Inc.$LYRA
Common Stock
2023-05-31$2.43/sh+1,203,612→ 2,521,745 total
Purchase
Lyra Therapeutics, Inc.$LYRA
Warrant to purchase Common Stock
2023-05-31$0.13/sh+601,806→ 601,806 total
Purchase
Lyra Therapeutics, Inc.$LYRA
Warrant to purchase Common Stock
2023-05-31$0.13/sh+201,929→ 201,929 total
Purchase
Lyra Therapeutics, Inc.$LYRA
Common Stock
2023-05-31$2.43/sh+197,946→ 1,107,370 total
Purchase
Lyra Therapeutics, Inc.$LYRA
Warrant to purchase Common Stock
2023-05-31$0.13/sh+98,973→ 98,973 total
Purchase
Lyra Therapeutics, Inc.$LYRA
Common Stock
2023-05-31$2.43/sh+403,858→ 2,259,301 total
Purchase
Lyra Therapeutics, Inc.$LYRA
Common Stock
2022-04-12$4.22/sh+1,076,851→ 1,855,443 total
Purchase
Lyra Therapeutics, Inc.$LYRA
Common Stock
2022-04-12$4.22/sh+765,010→ 1,318,133 total
Purchase
Lyra Therapeutics, Inc.$LYRA
Common Stock
2022-04-12$4.22/sh+527,806→ 909,424 total
Conversion
Lyra Therapeutics, Inc.$LYRA
Series C Convertible Preferred Stock
2020-05-05−2,420,729→ 0 total
Conversion
Lyra Therapeutics, Inc.$LYRA
Common Stock
2020-05-05+471,929→ 471,929 total
Conversion
Lyra Therapeutics, Inc.$LYRA
Series A-3 Convertible Preferred Stock
2020-05-05−4,587,608→ 0 total
Conversion
Lyra Therapeutics, Inc.$LYRA
Series A-1/C Convertible Preferred Stock
2020-05-05−1,495,786→ 0 total
Conversion
Lyra Therapeutics, Inc.$LYRA
Series A-1/A Convertible Preferred Stock
2020-05-05−1,157,670→ 0 total
Conversion
Lyra Therapeutics, Inc.$LYRA
Series A-4 Convertible Preferred Stock
2020-05-05−1,835,743→ 0 total
Conversion
Lyra Therapeutics, Inc.$LYRA
Series A-2 Convertible Preferred Stock
2020-05-05−2,088,772→ 0 total
Conversion
Lyra Therapeutics, Inc.$LYRA
Series A-2 Convertible Preferred Stock
2020-05-05−3,270,702→ 0 total
Conversion
Lyra Therapeutics, Inc.$LYRA
Common Stock
2020-05-05+319,303→ 319,303 total
Conversion
Lyra Therapeutics, Inc.$LYRA
Series B Convertible Preferred Stock
2020-05-05−3,124,633→ 0 total
Conversion
Lyra Therapeutics, Inc.$LYRA
Series A-1/A Convertible Preferred Stock
2020-05-05−1,725,090→ 0 total
Conversion
Lyra Therapeutics, Inc.$LYRA
Series C Convertible Preferred Stock
2020-05-05−1,545,953→ 0 total
Conversion
Lyra Therapeutics, Inc.$LYRA
Series A-4 Convertible Preferred Stock
2020-05-05−3,745,346→ 0 total
Conversion
Lyra Therapeutics, Inc.$LYRA
Series A-1/C Convertible Preferred Stock
2020-05-05−3,051,758→ 0 total
Exercise of In-Money
Lyra Therapeutics, Inc.$LYRA
Common Stock
2020-05-05$8.63/sh+21,060→ 672,513 total
Conversion
Lyra Therapeutics, Inc.$LYRA
Series A-2 Convertible Preferred Stock
2020-05-05−1,603,102→ 0 total
Exercise of In-Money
Lyra Therapeutics, Inc.$LYRA
Common Warrants
2020-05-05−21,060→ 0 total
Exercise of In-Money
Lyra Therapeutics, Inc.$LYRA
Common Stock
2020-05-05$8.63/sh+13,449→ 485,378 total
Exercise of In-Money
Lyra Therapeutics, Inc.$LYRA
Common Stock
2020-05-05$8.63/sh+10,322→ 329,625 total
Sale
Lyra Therapeutics, Inc.$LYRA
Common Stock
2020-05-05$16.00/sh−11,360→ 661,153 total
Sale
Lyra Therapeutics, Inc.$LYRA
Common Stock
2020-05-05$16.00/sh−7,255→ 478,123 total
Conversion
Lyra Therapeutics, Inc.$LYRA
Series A-3 Convertible Preferred Stock
2020-05-05−2,929,790→ 0 total
Conversion
Lyra Therapeutics, Inc.$LYRA
Common Stock
2020-05-05+651,453→ 651,453 total
Exercise of In-Money
Lyra Therapeutics, Inc.$LYRA
Common Warrants
2020-05-05−13,449→ 0 total
Purchase
Lyra Therapeutics, Inc.$LYRA
Common Stock
2020-05-05$16.00/sh+117,439→ 778,592 total
Conversion
Lyra Therapeutics, Inc.$LYRA
Series A-1/B Convertible Preferred Stock
2020-05-05−1,105,754→ 0 total
Sale
Lyra Therapeutics, Inc.$LYRA
Common Stock
2020-05-05$16.00/sh−5,568→ 324,057 total
Conversion
Lyra Therapeutics, Inc.$LYRA
Series C Convertible Preferred Stock
2020-05-05−1,186,496→ 0 total
Purchase
Lyra Therapeutics, Inc.$LYRA
Common Stock
2020-05-05$16.00/sh+57,561→ 381,618 total
Purchase
Lyra Therapeutics, Inc.$LYRA
Common Stock
2020-05-05$16.00/sh+75,000→ 553,123 total
Conversion
Lyra Therapeutics, Inc.$LYRA
Series A-1/A Convertible Preferred Stock
2020-05-05−567,420→ 0 total
Conversion
Lyra Therapeutics, Inc.$LYRA
Series B Convertible Preferred Stock
2020-05-05−1,531,507→ 0 total
Conversion
Lyra Therapeutics, Inc.$LYRA
Series B Convertible Preferred Stock
2020-05-05−1,995,489→ 0 total
Conversion
Lyra Therapeutics, Inc.$LYRA
Series A-4 Convertible Preferred Stock
2020-05-05−2,391,895→ 0 total
Exercise of In-Money
Lyra Therapeutics, Inc.$LYRA
Common Warrants
2020-05-05−10,322→ 0 total
Conversion
Lyra Therapeutics, Inc.$LYRA
Series A-1/B Convertible Preferred Stock
2020-05-05−541,973→ 0 total
Conversion
Lyra Therapeutics, Inc.$LYRA
Series A-1/B Convertible Preferred Stock
2020-05-05−1,647,727→ 0 total
Conversion
Lyra Therapeutics, Inc.$LYRA
Series A-3 Convertible Preferred Stock
2020-05-05−2,248,569→ 0 total
Conversion
Lyra Therapeutics, Inc.$LYRA
Series A-1/C Convertible Preferred Stock
2020-05-05−1,948,948→ 0 total
Disposition from Tender
MAVENIR SYSTEMS INC
Common Stock
2015-04-29$17.55/sh−1,695,587→ 0 total
Disposition from Tender
MAVENIR SYSTEMS INC
Common Stock
2015-04-29$17.55/sh−831,072→ 0 total

Companies

Recent Filings

Address

C/O NORTH BRIDGE VENTURE PARTNERS 950 WINTER STREET, SUITE 4600

WALTHAM, MA, 02451

View on SEC.gov